Loading...

Home
ETF
BCAX

BCAX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

BCAX News

Bicara Therapeutics Reports Efficacy Data for 750mg Dose of Ficerafusp Alfa

Dec 06 2025Globenewswire

Bicara Therapeutics Reports 57% Response Rate for 750mg Ficerafusp Alfa in HNSCC Study

Dec 06 2025Newsfilter

Bicara Reports Ficerafusp Alfa Clinical Data, 57% Response Rate at 750mg Dose

Dec 01 2025Newsfilter

Reassessing Biotech Pipelines: The Valuation Indicator Investors Have Anticipated

Nov 20 2025Globenewswire

Wells Fargo Keeps Equal-Weight Rating on Bicara Therapeutics and Increases Price Target to $11

Nov 11 2025Benzinga

Bicara Therapeutics Reports Reduced Net Loss in Q3

Nov 10 2025Yahoo Finance

What’s Driving Bicara Therapeutics' Pre-Market Surge?

Oct 13 2025NASDAQ.COM

Bicara Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for Ficerafusp Alfa in First-Line Treatment of HPV-Negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Oct 13 2025Newsfilter

Bicara Therapeutics submits $400M mixed securities shelf registration

Oct 03 2025SeekingAlpha

Analysts Predict 10% Growth Potential for SCHB Holdings

Oct 02 2025NASDAQ.COM

Piper Sandler Begins Coverage of Bicara Therapeutics with an Overweight Rating and Sets Price Target at $36

Aug 19 2025Benzinga

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12 2025Newsfilter

Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

Jul 31 2025Newsfilter

Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

Jul 21 2025Newsfilter

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

Jun 11 2025Newsfilter

Bicara Therapeutics Reports Promising Phase 1/1b Trial Results for Ficerafusp Alfa in HPV-Negative Head and Neck Cancer

Jun 01 2025NASDAQ.COM